VIR Earnings & Financial Statements
Vir Biotechnology, Inc.
$10.41
-$0.20(-1.89%)
57
Overall
60
Value
66
Tech
47
Quality
Market Cap
$1.76B
Volume
2.77M
52W Range
$4.82 - $12.00
Target Price
$21.00
VIR earnings and financial statements: Vir Biotechnology, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
VIR Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $68.56M | $74.20M | $86.18M | $1.58B | $1.09B |
| Cost of revenue | $26.0K | $845.0K | $2.77M | $146.32M | $65.86M |
| Operating income | -$479.33M | -$587.16M | -$684.30M | $833.07M | $420.75M |
| EBITDA | -$426.09M | -$508.55M | -$608.74M | $761.08M | $426.56M |
| Net income | -$437.99M | -$521.96M | -$615.06M | $515.84M | $528.58M |
| EPS (diluted) | $-3.16 | $-3.83 | $-4.59 | $3.83 | $3.96 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $1.00B | $1.40B | $1.92B | $2.80B | $1.95B |
| Total liabilities | $237.55M | $248.43M | $328.82M | $724.13M | $522.42M |
| Shareholders’ equity | $763.05M | $1.15B | $1.59B | $2.08B | $1.43B |
| Cash and equivalents | $232.19M | $222.95M | $241.58M | $848.63M | $347.81M |
| Long-term debt | $89.05M | $90.14M | $111.67M | $123.84M | $133.56M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$391.78M | -$446.35M | -$778.78M | $1.66B | -$47.59M |
| Capital expenditure | -$4.58M | -$3.93M | -$21.57M | -$68.01M | -$21.82M |
| Free cash flow | -$396.61M | -$453.65M | -$800.36M | $1.60B | -$69.41M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | VIR | $10.41 | -1.9% | 2.77M |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |